Loading
Combinations used off-label in over 200 patients in clinico-genomic databases can be analysed by target trial emulation. Emulations cannot replace trials, but they can rule out the pairs with no signal and flag those with large effects before money is spent on randomised studies.
Target trial emulation with clinico-genomic databases can estimate effects of combinations that are used in practice but never randomised. Emulations cannot replace trials but can deprioritise pairs with no signal and flag those with large effects. The proposal is a standing programme that emulates every combination used in over 200 patients in the database and publishes ranked results with pre-registered protocols.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Tempus AI, Too many combinations to test, Real-world evidence.
Shares Foundation Medicine (Roche), Tempus AI, Real-world evidence, Weak real-world evidence and registries.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Tempus AI, Real-world evidence, Weak real-world evidence and registries.
Shares AACR Project GENIE, Real-world evidence, Weak real-world evidence and registries.
Shares AACR Project GENIE, Foundation Medicine (Roche), Tempus AI, Weak real-world evidence and registries.
Shares AACR Project GENIE, Real-world evidence, Weak real-world evidence and registries.